Peginterferon alfa-2b(Merck & Co)

– Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include: Interim results for two years from the ASSURE study which evaluate the long-term efficacy and safety pro investigational seladelpar for the treatment of primary biliary cholangitis (PBC); Results of a pooled analysis, showcasing the effects of tenofovir-based antiviral therapy in reducing long-term incidence of primary liver cancer in people living with chronic hepatitis B (HBV); Final results of the Phase 2b MYR204 study evaluating the efficacy and safety of Hepcludex® (bulevirtide) in combination with pegylated interferon alfa-2a (PegIFN) in patients with compensated chronic hepatitis delta virus (HDV); and A late breaker presentation on the final results from the pivotal MYR301 Phase 3 study evaluating the efficacy and safety of bulevirtide as monotherapy. “These data underline Gilead’s commitment to drive life-changing science and create healthier futures for people living with liver disease. We look forward to presenting our latest research at EASL, as we strive to deliver novel medicines to populations with high unmet medical need,” said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences. “The breadth of our data being presented across viral and inflammatory liver diseases, speaks to our commitment to driving positive change at every step of a person’s journey. Transforming lives goes beyond treatment, and our research, innovation and partnerships span initial awareness and education, through to screening, diagnosis, path to care and ongoing management to address current unmet needs.” To drive efforts in supporting the World Health Organization’s (WHO) goal to eliminate viral hepatitis as a public health threat by 2030, Gilead will also present real-world data in hepatitis C (HCV) and launch a national HCV awareness program in Italy to raise awareness of the disease. In collaboration with EASL, Gilead will launch “Epatite C Mettiamoci un Punto” (Hepatitis C Let’s Put a Stop to it) in Milan to raise awareness about the disease and encourage people to get tested for HCV through EASL’s “Love Your Liver” Campaign. Advancing Treatment options in PBC New data demonstrating the long-term efficacy and safety pro investigational seladelpar for the treatment of primary biliary cholangitis (PBC) will be presented at EASL. These include the first interim data from the Phase 3 open-label ASSURE study that includes people who received a second year of seladelpar treatment following their initial participation in the Phase 3 RESPONSE study. The study also includes patients with insufficient response to first-line PBC treatment, ursodeoxycholic acid (UDCA). These data evaluate the composite biochemical response (alkaline phosphatase (ALP) < 1.67x upper limit of normal (ULN), ALP decrease ≥ 15%, and total bilirubin ≤ ULN) and ALP normalization, as well as pruritus for seladelpar in the treatment of PBC which is a rare, chronic, cholestatic liver disease mainly affecting women (1 in 1,000 women over the age of 40 or about 130,000 total people in the U.S.) that impairs liver function and quality of life. The most common early symptoms of PBC are pruritus (itching) and fatigue, which can be debilitating for some patients. Progression of PBC is associated with an increased risk of liver-related mortality. Key Findings in HDV At the EASL Congress, Gilead will present 13 abstracts in HDV, including the Week 144 (48 Weeks off-treatment) results of the Phase 2b MYR204 study of bulevirtide with or without peginterferon alfa-2a (PegIFN) in people with chronic HDV and compensated liver disease (GS-002), and results from the pivotal Phase 3 MYR301 study assessing the efficacy and safety of bulevirtide as monotherapy as a late-breaker presentation (LB-309). Further highlighting Gilead as a leader in HDV research, a sub-analysis of the MYR204 study (OS-122) evaluating intrahepatic virological outcomes 24 Weeks off-treatment will be presented. A pooled analysis of the MYR203, MYR204 and MYR301 studies (TOP-400) discussing the impact of nucleos(t)ide analogues alongside bulevirtide 48 Weeks off-treatment will also be shared as an oral presentation. These data evaluate the efficacy pro bulevirtide for people living with HDV, which is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure, liver cancer and liver-related death. Key Abstracts at EASL 2024: ID Abstract Title PBC OS-019 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim results THU-098 Appraising gain of an extended 2-year placebo-controlled trial in primary biliary cholangitis: challenges for evaluating clinical outcomes SAT-175 PPAR-delta activation with seladelpar regulates cholangiocyte inflammation THU-119 Seladelpar treatment increases fatty acid beta-oxidation and serum carnitine levels in patients with primary biliary cholangitis consistent with increased expression of the carnitine transporter OCTN2 and the mitochondrial carnitine shuttle SAT-177 Assessment of PPAR-delta target engagement in mouse liver assessed by single nuclei sequencing following a single oral dose of seladelpar LB-283 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interim results for 2 years from the ASSURE study HDV GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: Final results from MYR204 LB-309 Efficacy and safety of 144 weeks of bulevirtide 2 mg or 10 mg monotherapy from the ongoing Phase 3 study, MYR301 TOP-400 Impact of bulevirtide given with or without nucleos(t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection WED-395 Undetectable hepatitis delta virus RNA at the end of treatment with bulevirtide and pegylated interferon alpha-2a is an important predictor of 48 weeks sustained virologic response in chronic hepatitis delta OS-122 Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver FRI-435 Serological and nucleic acid testing laboratory screening rates for hepatitis delta virus among adult patients in the United States HCV THU-374 Description of age, sex, and characteristics of hepatitis C patients in the SVR10K study: a real-world SOF/VEL analysis performed across five global regions WED-498 Impact of direct acting antiviral market access policy barriers and restrictions for Hepatitis C patients: a database analysis of claims from states with and without Medicaid restrictions WED-447 Age at incident cirrhosis in individuals with hepatitis C virus infection: a US administrative claims analysis HBV WED-397 Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B patients FRI-390 Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus MASH/Fibrosis TOP-264 Paired assessment of Enhanced Liver Fibrosis (ELF) and Fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in patients with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH) For more information, including a complete list of abstract titles being presented at the meeting, please visit the EASL website. In July 2023, the European Commission (EC) granted full Marketing Authorization (MA) for bulevirtide 2 mg for the treatment of adults with chronic HDV and compensated liver disease. Bulevirtide was initially granted conditional MA from the EC in July 2020 to provide access to people living with HDV urgent access to treatment. Bulevirtide also received full MA in Great Britian in August 2023 and in Switzerland in February 2024. In the U.S. and outside of the European Economic Area, bulevirtide is an investigational agent that is not approved for any use. In these regions, health authorities have not established the safety and efficacy of bulevirtide. Bulevirtide 10 mg is an investigational product and has not been approved anywhere globally. Seladelpar is an investigational compound and is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority; its safety and efficacy have not been established. About PBC PBC is a rare, chronic inflammatory liver disease primarily affecting women (1 in 1,000 women over the age of 40 or about 130,000 total people in the US). PBC is characterized by impaired bile flow (known as cholestasis) and the accumulation of toxic bile acids in the liver, leading to inflammation and destruction of the bile ducts within the liver and causing increased levels of ALP, ALT, and GGT, enzymes found primarily in the liver, as well as total bilirubin. The most common early symptoms of PBC are pruritus (itching) and fatigue, which can be debilitating for some patients. Progression of PBC is associated with an increased risk of liver-related mortality. About HDV HDV is considered the most aggressive or severe form of viral hepatitis, associated with more rapid progression towards liver-related death and liver cancer in people with hepatitis B (HBV). On average, HDV progresses to cirrhosis within 5 years and to liver cancer within 10 years. Nearly 5% of people who have a chronic infection with HBV are estimated to have HDV, equating to 12-15 million people worldwide. The prevalence of HDV infection is largely underestimated due to lack of universal testing of HBV-positive individuals for HDV. About Gilead Sciences in Liver Disease For decades, Gilead has pioneered the way forward to improve the lives of people living with liver disease around the world. We have helped transform hepatitis C from a chronic condition into one that can be cured for millions of people. For people living with hepatitis B or D, our focus on advancing our medicines drives hope that today’s research will turn into tomorrow’s cures. Beyond viral hepatitis, we’re working to deliver advanced treatments for people living with primary biliary cirrhosis (PBC). But our commitment doesn’t stop there. Through our ground-breaking science and collaborative partnerships, we strive to create healthier futures for everyone living with liver disease. We are committed to a future without liver disease. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to initiate, progress or complete clinical trials or studies within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials or studies, including those involving Hepcludex (bulevirtide) and seladelpar; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that the FDA and other regulatory authorities may not approve bulevirtide for the treatment of HDV and/or seladelpar for the treatment of PBC, and the risk that any such approvals, if granted, may be subject to significant limitations on use; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements. Hepcludex, Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies. For more information about Gilead, please visit the company’s website at , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 billion in cash, cash equivalents and investments as of March 31, 2024 – – Conference call scheduled for May 2, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – SAN FRANCISCO--(BUSINESS WIRE)-- VIR BIOTECHNOLOGY, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. “We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings us closer to addressing the significant unmet medical need for the millions of people living with hepatitis delta,” said Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer. “Our team has worked diligently to streamline our operations and reduce costs, enabling us to focus our resources on advancing our promising clinical programs in hepatitis delta and hepatitis B. Looking ahead, we anticipate additional data readouts in the fourth quarter that could serve as important catalysts for the company.” Pipeline Programs Chronic Hepatitis Delta (CHD) On March 5, 2024, Vir announced its Phase 2 chronic hepatitis delta SOLSTICE trial completed enrollment of its current cohorts one month ahead of schedule with over 60 participants enrolled in two additional cohorts. The trial is evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta. One cohort is evaluating the combination of tobevibart and elebsiran given every 4 weeks with a second cohort evaluating tobevibart monotherapy given every 2 weeks. Approximately 50% of participants have compensated cirrhosis. The Company will report data on a subset of SOLSTICE participants in a late-breaker poster presentation at the EASL Congress 2024. This includes additional 12-week treatment data on approximately 30 participants (~15 per regimen) and 24-week treatment data on approximately 20 participants (~10 per regimen). Additional follow-up data for the initial six SOLSTICE trial participants will also be shared at the EASL Congress 2024. Complete 24-week treatment data is expected in the fourth quarter of 2024. Chronic Hepatitis B (CHB) Two abstracts have been accepted for poster presentation at the EASL Congress 2024. The Phase 2 MARCH Part B trial is fully enrolled with 48-week end of treatment data expected in the fourth quarter of 2024. The trial is evaluating the safety, tolerability and antiviral activity of the combination of tobevibart and elebsiran with and without peginterferon alpha. Initial data from the Phase 2 PREVAIL platform trial and its THRIVE/STRIVE sub-protocols is expected in the first half of 2025. These trials are evaluating combinations of tobevibart, elebsiran and/or peginterferon alpha in two patient populations: immune-active but treatment-naïve and inactive carriers. Human Immunodeficiency Virus (HIV) Part A of the Phase 1 trial of VIR-1388, an investigational novel T cell vaccine for the prevention of HIV, is fully enrolled with initial immunogenicity data expected in the second half of 2024. The trial is supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Bill & Melinda Gates Foundation, and is being conducted by the HIV Vaccine Trials Network. Influenza On April 4, 2024, the Company published the full data analysis from the Phase 2 PENINSULA trial evaluating VIR-2482 on medRxiv. Preclinical Pipeline Candidates Vir is continuing to advance next-generation antibodies using its proprietary platform, which leverages dAIsY™ (data AI structure and antibody), the Company’s proprietary AI engine, enabling the Company to bring high-quality drug candidates to the clinic more efficiently. The Company expects the filing of multiple investigational new drug applications within the next 18 months, including: VIR-1949, an investigational therapeutic T cell vaccine based on Vir’s human cytomegalovirus (HCMV) vector platform that is designed to treat precancerous lesions caused by the human papillomavirus. VIR-7229, a next-generation COVID monoclonal antibody candidate that has been AI-engineered to have increased potency, breadth and resistance to viral escape. The development of VIR-7229 has been supported in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081. VIR-2981, an investigational neuraminidase-targeting monoclonal antibody against both influenza A and B viruses. VIR-8190 and other investigational monoclonal antibodies against respiratory syncytial virus and/or metapneumovirus as part of the collaboration established with GSK in May of 2021. Corporate Update The Company plans to host a virtual R&D day in late November. Effective May 3, 2024, Sung Lee, Executive Vice President and Chief Financial Officer will be stepping down from his role to pursue another career opportunity. The Company has initiated a search for a successor. First Quarter 2024 Financial Results Cash, Cash Equivalents and Investments: As of March 31, 2024, the Company had approximately $1.51 billion in cash, cash equivalents and investments. Cash, cash equivalents and investments declined by approximately $118 million during the first quarter of 2024. Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023. Revenues were comprised of the following components: Three Months Ended March 31, 2024 2023 % Change (in millions) Collaboration revenue $ (1.0 ) $ 46.6 (102.1 )% Contract revenue 52.2 0.1 >100.0 % Grant revenue 5.2 16.2 (67.9 )% Total revenues $ 56.4 $ 63.0 (10.5 )% Note: Numbers may not add due to rounding. Collaboration revenue: The decrease in collaboration revenue for the first quarter of 2024 compared to the same period in 2023 was driven by the release of profit-sharing amount previously constrained during the three months ended March 31, 2023 and to a lesser extent, lower sales of sotrovimab during the three months ended March 31, 2024, under the Company’s collaboration with GSK. Contract revenue: The increase in contract revenue for the first quarter of 2024 compared to the same period in 2023 was primarily driven by the recognition of deferred revenue related to the expiry of GSK’s rights to select up to two additional non-influenza target pathogens during the three months ended March 31, 2024. Grant revenue: The decrease in grant revenue was primarily driven by lower revenue related to the Company's agreement with BARDA. Cost of Revenue: Cost of revenue for the first quarter of 2024 was nominal compared to $1.9 million for the same period in 2023. The decrease was due to lower third-party royalties owed on the sales of sotrovimab. Research and Development Expenses (R&D): R&D expenses for the first quarter of 2024 were $100.1 million, which included $13.6 million of non-cash stock-based compensation expense, compared to $157.6 million for the same period in 2023, which included $13.4 million of non-cash stock-based compensation expense. The decrease was primarily driven by lower clinical development costs and manufacturing costs associated with VIR-2482. Selling, General and Administrative Expenses (SG&A): SG&A expenses for the first quarter of 2024 were $36.3 million, which included $10.2 million of non-cash stock-based compensation expense, compared to $46.8 million for the same period in 2023, which included $12.1 million of non-cash stock-based compensation expense. The decrease was primarily driven by cost savings initiatives implemented during the second half of 2023. Other Income: Other income for the first quarter of 2024 was $15.1 million compared to $0.2 million for the same period in 2023. The increase was primarily due to the decrease in foreign exchange loss related to remeasurement of liability reserved for excess sotrovimab supply and manufacturing capacity and a decrease in loss recognized on the Company's equity investments. (Provision for) Benefit from Income Taxes: Provision for income taxes for the first quarter of 2024 was $0.3 million compared to benefit from income taxes of $2.2 million for the same period in 2023. Net Loss: Net loss attributable to Vir for the first quarter of 2024 was $(65.3) million, or $(0.48) per share, basic and diluted, compared to a net loss of $(140.9) million, or $(1.06) per share, basic and diluted for the same period in 2023. 2024 Financial Guidance The Company reiterates its full year 2024 guidance below, originally provided on February 22, 2024 (in millions): GAAP combined R&D and SG&A expense range: $ 650 to $ 680 The following expenses are included in the GAAP combined R&D and SG&A expense range: Stock-based compensation expense $ 115 to $ 105 Restructuring charges* $ 35 to $ 25 * Restructuring charges are primarily non-cash expenditures, related to the closing of two R&D sites previously announced on December 13, 2023. Approximately three to four percent of the GAAP combined R&D and SG&A expense will be funded by grants. These grants are recognized as revenue. The GAAP combined R&D and SG&A expense guidance does not include the effect of GAAP adjustments caused by events that may occur subsequent to the publication of this guidance, including, but not limited to, business development activities, litigation, in-process R&D impairments, and changes in the fair value of contingent considerations. Conference Call Vir will host a conference call to discuss the first quarter results at 1:30 p.m. PT / 4:30 p.m. ET today. A live webcast will be available on and will be archived on for 30 days. About Tobevibart Tobevibart is an investigational subcutaneously administered antibody designed to block entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. Tobevibart, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to potentially function as a T cell vaccine against hepatitis B virus and hepatitis delta virus, as well as to have an extended half-life. Tobevibart was identified using Vir’s proprietary monoclonal antibody discovery platform. About Elebsiran Elebsiran is an investigational subcutaneously administered hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) that Vir believes has the potential to stimulate an effective immune response and have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially could result in an increased therapeutic index. Elebsiran is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials. About VIR-2482 VIR-2482 is an investigational hemagglutinin targeting, intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 flu pandemic. VIR-2482 is designed as a prophylactic for influenza A. VIR-2482 incorporates Xencor’s Xtend™ and was identified using Vir’s proprietary monoclonal antibody discovery platform. The PENINSULA trial has been supported in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081. About VIR-2981 VIR-2981 is an investigational neuraminidase-targeting monoclonal antibody against influenza viruses. It targets a region of the neuraminidase protein that is highly conserved across influenza A and B strains and is designed to inhibit the influenza neuraminidase, a key viral protein that facilitates release of new viruses in infected individuals. Preclinical data demonstrate the antibody’s breadth and potency against all major strains of seasonal and pandemic influenza viruses and support the potential of this antibody in the prevention of influenza illness. VIR-2981 was identified using Vir’s proprietary monoclonal antibody discovery platform. About VIR-1388 VIR-1388 is a preclinical subcutaneously administered HIV T cell vaccine based the T cell-based viral vector platform and has been designed to elicit abundant T cells that recognize HIV epitopes with the goal of creating a safe and effective HIV vaccine. About Sotrovimab Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody that was developed in collaboration with GSK. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS). Sotrovimab, which incorporates Xencor, Inc.’s Xtend™ technology, has been designed to achieve high concentration in the lungs to achieve optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. Sotrovimab was identified using Vir’s proprietary monoclonal antibody discovery platform. Sotrovimab is currently not authorized in the US. About VIR-7229 VIR-7229 is an investigational next generation COVID-19 monoclonal antibody with a distinct combination of potency, breadth and viral inescapability. VIR-7229 is designed as a prophylactic for COVID-19 and was identified using Vir’s proprietary monoclonal antibody discovery platform. VIR-7229 incorporates Xencor, Inc.’s Xtend™ technology and is affinity matured using machine learning to increase its effectiveness in binding to SARS-CoV and SARS-CoV-2 variants. The development of VIR-7229 has been supported in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081. About VIR-8190 VIR-8190 is an investigational dual specificity monoclonal antibody that has the ability to potently neutralize both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) strains. RSV and HMPV are recognized as significant causes of lower respiratory tract disease in high-risk populations, including infants and immunocompromised individuals. VIR-8190 was identified using Vir’s proprietary mAb discovery platform. About VIR-1949 VIR-1949 is an investigational therapeutic vaccine based the T cell-based viral vector platform that is designed to treat HPV-related high-grade squamous epithelial pre-cancer lesions (HSIL) and cancers. This vaccine uses HCMV as the vaccine vector. Based on preclinical data, HCMV vectors have the potential to induce high frequencies of antigen-specific, tissue-localizing effector memory T cells. About Vir Biotechnology, Inc. Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans; Vir’s cash balance; Vir’s financial guidance; Vir’s future financial and operating results and its expectations related thereto; potential of, and expectations for, Vir’s pipeline; Vir’s clinical and preclinical development programs, clinical trials, including the enrollment of Vir’s clinical trials, and the expected timing of data readouts and presentations; the potential benefits, safety, and efficacy of Vir’s investigational therapies; and risks and uncertainties associated with drug development and commercialization. Many important factors may cause differences between current expectations and actual results, including uncertainty as to whether the anticipated benefits of the BARDA collaboration can be achieved; unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the timing and outcome of Vir’s planned interactions with regulatory authorities; difficulties in obtaining regulatory approval; uncertainty as to whether the anticipated benefits of Vir’s collaborations with other companies can be achieved; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; clinical site activation rates or clinical trial enrollment rates that are lower than expected; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials, Vir’s use of artificial intelligence and machine learning in its efforts to engineer next-generation proteins and in other research and development efforts; the timing and amount of actual expenses, including, without limitation, Vir’s anticipated combined GAAP R&D and SG&A expenses; geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. VIR BIOTECHNOLOGY, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) March 31, 2024 December 31, 2023 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 160,711 $ 241,576 Short-term investments 985,125 1,270,980 Restricted cash and cash equivalents, current 13,335 13,268 Equity investments 3,927 9,853 Prepaid expenses and other current assets 49,999 52,549 Total current assets 1,213,097 1,588,226 Intangible assets, net 22,465 22,565 Goodwill 16,937 16,937 Property and equipment, net 92,477 96,018 Operating lease right-of-use assets 70,346 71,182 Restricted cash and cash equivalents, noncurrent 6,428 6,448 Long-term investments 359,724 105,275 Other assets 12,495 12,409 TOTAL ASSETS $ 1,793,969 $ 1,919,060 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable $ 7,114 $ 6,334 Accrued and other liabilities 72,260 104,220 Deferred revenue, current 14,694 64,853 Total current liabilities 94,068 175,407 Deferred revenue, noncurrent 1,526 1,526 Operating lease liabilities, noncurrent 109,171 111,673 Contingent consideration, noncurrent 27,610 25,960 Other long-term liabilities 14,238 14,258 TOTAL LIABILITIES 246,613 328,824 Commitments and contingencies (Note 8) STOCKHOLDERS’ EQUITY: Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 — — Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 135,843,560 and 134,781,286 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 14 13 Additional paid-in capital 1,852,839 1,828,862 Accumulated other comprehensive loss (2,397 ) (815 ) Accumulated deficit (303,100 ) (237,824 ) TOTAL STOCKHOLDERS’ EQUITY 1,547,356 1,590,236 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 1,793,969 $ 1,919,060 VIR BIOTECHNOLOGY, INC. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended March 31, 2024 2023 Revenues: Collaboration revenue $ (987 ) $ 46,574 Contract revenue 52,191 138 Grant revenue 5,172 16,245 Total revenues 56,376 62,957 Operating expenses: Cost of revenue 59 1,907 Research and development 100,125 157,643 Selling, general and administrative 36,273 46,778 Total operating expenses 136,457 206,328 Loss from operations (80,081 ) (143,371 ) Other income: Change in fair value of equity investments (5,915 ) (13,103 ) Interest income 21,283 21,307 Other expense, net (287 ) (8,021 ) Total other income 15,081 183 Loss before (provision for) benefit from income taxes (65,000 ) (143,188 ) (Provision for) benefit from income taxes (276 ) 2,232 Net loss (65,276 ) (140,956 ) Net loss attributable to noncontrolling interest — (56 ) Net loss attributable to Vir $ (65,276 ) $ (140,900 ) Net loss per share attributable to Vir, basic and diluted $ (0.48 ) $ (1.06 ) Weighted-average shares outstanding, basic and diluted 135,280,648 133,552,839